Nuode Pharmaceutical (Jiangsu) Co., Ltd.

Primary objective: To evaluate the bioequivalence of the two preparations in fasting and postprandial states in healthy Chinese subjects, using the reference preparation of Aguratimod tablets (trade name: Edexin, specification: 25 mg) produced by Hainan Xiansheng Pharmaceutical Co., Ltd. as the reference preparation and the test preparation of Aguratimod tablets (25 mg) developed by Jiangsu Yuexing Pharmaceutical Co., Ltd. as the test preparation. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.

Bilastine tablets (specification: 20 mg) produced by Jiangsu Yuexing Pharmaceutical Co., Ltd. were used as the test preparation, and Bilastine tablets (trade name: BILAXTEN, specification: 20 mg) produced by FAES FARMA, S.A. were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations after single administration under fasting conditions were investigated to evaluate whether the two preparations were bioequivalent. At the same time, the safety and tolerability of the two preparations in healthy humans were evaluated.

Primary objective: To compare the absorption rate and extent of rosuvastatin calcium tablets produced by Jiangsu Yuexing Pharmaceutical Co., Ltd. (trade name: Crestor®, reference preparation) in healthy human bodies with those produced by IPR Pharmaceuticals, Inc., and to investigate the bioequivalence of the two preparations in humans. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.